Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemcitabine-mediated radiosensitization

T S Lawrence1, A Eisbruch, D S Shewach

  • 1Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor 48109-0582, USA.

Seminars in Oncology
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diffusion MRI correlation with p16 status and prediction for tumor progression in locally advanced head and neck cancer.

Frontiers in oncology·2024
Same author

Response to Kibe Y et al. "Methodological concerns for investigating the effects of midtreatment break of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC)".

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2020
Same author

A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2019
Same author

Treatment data and technical process challenges for practical big data efforts in radiation oncology.

Medical physics·2018
Same author

Statistical controversies in clinical research: building the bridge to phase II-efficacy estimation in dose-expansion cohorts.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.

Oncogene·2016
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Gemcitabine effectively sensitizes human tumor cells to radiation, particularly for pancreatic, breast, and head and neck cancers. Careful dosing is crucial to maximize efficacy while minimizing normal tissue toxicity.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Cancer Biology

Background:

  • Gemcitabine is a nucleoside analog used in cancer chemotherapy.
  • Its role as a radiosensitizer requires further elucidation.
  • Preclinical and early clinical data are essential for optimizing its use with radiation therapy.

Purpose of the Study:

  • To review preclinical and early clinical studies on gemcitabine's mechanism of action as a radiosensitizer.
  • To determine the optimal dose and schedule for gemcitabine in combination with radiation.
  • To assess the potential of gemcitabine to enhance radiation therapy efficacy.

Main Methods:

  • Review of preclinical studies on gemcitabine's radiosensitizing effects on various human tumor cell lines.
  • Analysis of in vitro conditions leading to radiosensitization, including cell cycle redistribution and deoxyadenosine triphosphate pool depletion.

Related Experiment Videos

  • Summary of Phase I clinical trials investigating gemcitabine dose and schedule in combination with radiation.

    • Main Results:

    • Gemcitabine demonstrated radiosensitization in diverse human tumor cells, notably in pancreatic, breast, and head and neck cancers.
    • Radiosensitization was observed under conditions of S-phase redistribution and dATP pool depletion.
    • A brief, clinically relevant exposure to gemcitabine induced sensitization lasting up to two days.
    • Early clinical trials indicated that low-dose gemcitabine potentiated radiation toxicity in head and neck cancer patients.

    Conclusions:

    • Gemcitabine is a potent radiosensitizer with significant potential in cancer treatment.
    • Optimizing gemcitabine's dose and schedule is critical for balancing therapeutic benefit and toxicity.
    • Cautious development is advised to avoid excessive normal tissue damage when combining gemcitabine with radiation.